[Management of essential arterial hypertension].
Girerd
X
X
Service de Médecine interne, Hôpital Broussals, Paris.
D000319:Adrenergic beta-Antagonists / Q000008:administration & dosage / Q000627:therapeutic use; D000368:Aged; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use; D000959:Antihypertensive Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D017298:Bisoprolol / Q000008:administration & dosage / Q000627:therapeutic use; D004232:Diuretics / Q000008:administration & dosage / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D005602:France; D006801:Humans; D006852:Hydrochlorothiazide / Q000008:administration & dosage / Q000627:therapeutic use; D006973:Hypertension / Q000188:drug therapy*; D007190:Indapamide / Q000008:administration & dosage / Q000627:therapeutic use; D008875:Middle Aged; D018579:Patient Selection; D020913:Perindopril / Q000008:administration & dosage / Q000627:therapeutic use; D017410:Practice Guidelines as Topic; D011379:Prognosis; D012307:Risk Factors; D012955:Societies, Medical; D049993:Sodium Chloride Symporter Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use; D013997:Time Factors; D014944:World Health Organization
D000319:Adrenergic beta-Antagonists; D000806:Angiotensin-Converting Enzyme Inhibitors; D000959:Antihypertensive Agents; D004232:Diuretics; D049993:Sodium Chloride Symporter Inhibitors; D006852:Hydrochlorothiazide; D007190:Indapamide; D017298:Bisoprolol; D020913:Perindopril